Sclerodermatous chronic graft-versus-host-disease (cGVHD) is a distinctive phenotype of GVHD with a 20% incidence within 3 years of initial systemic treatment of cGVHD. 1 Sclerotic cGVHD resembles autoimmune systemic sclerosis (SSc) and does not respond adequately to immunosuppressive therapy (IST). Patients often experience muscle cramps and require prolonged therapy complicated by recurrent infections.
Intravenous (IV) lidocaine has been used successfully for treatment of refractory SSc, as documented by improved cutaneous blood flow. 2 Additionally, lidocaine affects collagen synthesis by reducing prolyl hydroxylase activity, and exerts antiinflammatory effects through interference with key functions of neutrophils and macrophages. 3 A case report described rapid improvement of symptoms and skin lesions in two patients with refractory sclerodermatous cGVHD treated with lidocaine infusions. 4 At our center, the use of IV lidocaine in patients with sclerotic cGVHD has been motivated by continued dependence on high doses of glucocorticoids and the lack of effective alternatives. We report a retrospective series of eight patients treated with IV lidocaine to expand on the current knowledge of this treatment for refractory sclerotic cGVHD. Between January 2005 and December 2007, we identified eight patients with sclerotic cGVHD treated with lidocaine infusions at doses of 400 mg (diluted in 250 mL of normal saline) over 3.5 h for 5 consecutive days every month (one cycle), 4 for a minimum of three cycles. All patients had cGVHD refractory to glucocorticoids and calcineurin inhibitors, and had previously received three or more lines of therapy. The decision to use lidocaine was made by the attending physician after informing the patient about potential risks, the reported anecdotal benefits and the uncertain success rate. Patients gave written consent allowing the use of medical records for research in accordance with the Declaration of Helsinki, and our institutional review board approved the study.
Response to lidocaine was assessed according to (1) the improvement in sclerosis as judged by end-of-treatment modified Rodnan skin score (RSS) and (2) the ability to reduce glucocorticoid dose. The RSS is a 51-point scale considering 17 body areas scored according to the degree of skin thickening. A medical professional trained in cGVHD assessed the patients. After at least three cycles, treatment was stopped if no improvement was seen. RSS assessments were not performed in one patient treated at another center.
The median patient age at starting lidocaine therapy was 50 years (range 33-70). Lidocaine was added as a steroid-sparing agent owing to the progressive cGVHD in seven patients. One refractory patient was not treated with glucocorticoids due to prior significant steroid-induced toxicity. The median number of involved cGVHD sites was 4. All patients had sclerosis (median RSS 14) and fasciitis. Other cGVHD features included bronchiolitis obliterans (BO) (n ¼ 2), weight loss (n ¼ 1), keratitis (n ¼ 4) and liver impairment (n ¼ 1). Median time from cGVHD diagnosis to lidocaine therapy was 61 months. The median number of prior systemic agents received was 5, and the median number of lidocaine cycles was 6. The infusions were well tolerated, with no reported arrhythmias, hypotension, hyperesthesia, psychosis, bronchospasm or seizures. IST was continued throughout the lidocaine treatment. Treatment with lidocaine was discontinued owing to the improved sclerosis with plateauing of response (n ¼ 3), lack of response (n ¼ 4) and insurance denial for continued therapy (n ¼ 1).
Patient outcomes are shown in Table 1 . Two patients had improved RSS and improved symptoms that resulted in cessation (n ¼ 1) or reduction (n ¼ 1) of glucocorticoid therapy. Two other patients reported symptomatic improvement but documentation of RSS was missing; one of these patients was able to reduce glucocorticoid dosing, while the other was able to discontinue the remaining systemic immunosuppression (mycophenolate). Sclerosis progressed in three patients and remained stable in another case. Fasciitis/joint manifestations improved in three patients and remained stable in the rest. All responding patients reported improvement in pain. BO and keratitis did not change with lidocaine. None of the patients developed new sites of cGVHD during therapy.
More than half of patients will require second-line IST within 2 years of initiating systemic treatment for cGVHD. 5 The reported efficacy of second-line agents varies widely due to different methods of response assessment, lack of uniformity in defining steroid-refractory disease and limitations of phase 2 and retrospective study designs. 6, 7 With no one agent proving to have superior efficacy, the choice of therapy relies on the clinician's expertise and sense of what is most appropriate given the particular manifestation of cGVHD and patient comorbidities. When the latter fails, empirical testing of second-line IST remains as the standard approach. Patients suffer from cGVHD-associated organ dysfunction, impaired immune function, compromised quality of life and increased risk of mortality. We became interested in lidocaine because of its reported efficacy in SSc patients and its lack of hematologic toxicity and infection risk.
The mechanisms underlying lidocaine's action in sclerosis is unclear. In vitro studies have shown that lidocaine inhibits the NFKb pathway in a dose-dependent manner, influencing production of the T-cell cytokines interleukin-2, tumor necrosis factor-a (TNFa), interferon-g 8 and IP-10. IP-10 interacts with CXCR3 to promote Th 1 -cell migration which may initiate cGVHD, while TNFa and interferon-g can induce aberrant human leukocyte antigen (HLA)-DR expression and increase susceptibility to cGVHD in certain organs. 9 Lidocaine infusions were safe and had a steroid-sparing effect in four patients, including one who managed to discontinue treatment with glucocorticoids. Some patients appeared to experience improvement in sclerosis and fasciitis but not in other GVHD manifestations. We acknowledge that the observed steroidsparing effect was based on glucocorticoid dose adjustments that were not carried out in the context of a controlled study but at the discretion of the treating physician depending on assessments of cGVHD activity and steroid-induced toxicity.
Interpretation of our results is limited by the retrospective nature of this review and the small cohort size. Indeed, in patients with SSc, improvements were not seen in a randomized, placebo-controlled trial that objectively measured the RSS. 10 Nonetheless, this report describes the safety of lidocaine infusions in patients with refractory sclerotic cGVHD. Our results should be viewed in the context of the toxicities, increased infection rates and variable responses seen with other available therapies. Prospective trials evaluating lidocaine therapy for sclerotic cGVHD are needed.
